Telithromycin also inhibited human nicotinic acetylcholine receptors expressed in oocytes. After 20 min at 2 μM, reported current inhibition was greater at α3β4 and α7 receptors than at α4β2 receptors. Muscle-type receptor responses partially recovered after washout, and comparable inhibition by other macrolides limited a telithromycin-specific explanation based on this receptor alone. [3]
Concentration–inhibition analysis reported telithromycin IC50 values of 0.1 μM at α3β4, about 0.15 μM at α7 and about 4 μM at α4β2 receptors. These values describe inhibition of ACh-evoked currents in the heterologous assay; they do not establish the cause of clinical adverse events. [3]
Two-step binding to a functional ribosomal complex
Biochemical assay · Cell-free, wild-type E. coli 70S post-translocation complex C, poly(U)-programmed with E-site tRNA and P-site AcPhe-tRNA. [1]
Competition with tylosin supported a rapid initial binding step followed by slow conversion to a tighter-binding state. Added spermine reduced apparent affinity. Telithromycin alone did not inhibit the puromycin reaction used as the functional readout.
Literature-Reported Treatment Conditions
- Treatment concentration
- Binding competition: 4 μM tylosin with varied telithromycin (Figure 2B: 0.5, 1, 2, 4 and 10 μM). Negative functional control: 2 μM telithromycin.
- Exposure duration
- Time-dependent binding; 15-min telithromycin preincubation in the preincubation comparison.
- Method
- Cell-free competition assay at 25°C; base ionic conditions 4.5 mM Mg2+ and 150 mM NH4+. Puromycin readout reports competition rather than direct inhibition by telithromycin.
- Co-treatment
- Tylosin is a competing assay ligand; these data are not evidence of therapeutic combination efficacy.
- Reported limits
- Telithromycin vehicle not specified in the selected binding methods. Binding constants depend on ionic conditions; mutant experiments and SI fit derivations are not adopted.
Methods and source locations
Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin
Cell-free ribosome engagement and assay-specific limitations.
Table 1; Figure 2A–C and caption; binding-kinetics Methods; Statistics
Initial-step equilibrium dissociation constant, wild-type complex C without added polyamines: Two-step competition model; mean ± SE, three independently performed experiments. — Table 1, first wild-type column and footnote; binding-kinetics Methods
Overall equilibrium dissociation constant, wild-type complex C without added polyamines: Calculated within the two-step model; mean ± SE, three independently performed experiments. — Table 1, first wild-type column and footnote; main-text Equation 1
Overall equilibrium dissociation constant, wild-type complex C with 100 μM spermine: Same model and base ionic conditions with added spermine; mean ± SE, three independently performed experiments. — Table 1, wild-type +100 μM spermine column and footnote
AcPhe-puromycin synthesis in the presence of 2 μM telithromycin: Figure 2A compares 200 μM puromycin alone, with 2 μM telithromycin, or with 2 μM tylosin at 25°C. No exact effect size inferred from the curve. — Figure 2A and caption; Results: Telithromycin behaves as a slow-binding ligand
Pressure-dependent interaction with purified LPS monolayers
Biochemical assay · Langmuir monolayers of purified E. coli Re-LPS and Rd-LPS, compared with no-antibiotic LPS isotherms. [2]
Telithromycin-containing isotherms differed from no-antibiotic controls in expanded films. The authors interpreted the pressure-dependent convergence as intercalation followed by expulsion during compression; direct cellular uptake was not measured.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.0, 3.0 and 10.0 μM
- Exposure duration
- Isotherms followed a 10-min start delay for solvent evaporation; measured within 24 h of antibiotic stock preparation.
- Method
- Pressure–area isotherms at 20 ± 1°C in pH 7.2 subphase containing 100 mM KCl, 3 mM Tris and 100 μM CaCl2.
- Vehicle
- Ethanol stock diluted into subphase; final ethanol fraction not stated separately for each trace.
- Co-treatment
- Telithromycin was tested individually; azithromycin was a separate comparator, not a combination.
- Reported limits
- Methods define no-antibiotic LPS controls; an explicitly matched ethanol-only control is not described in the selected methods. The monolayer model does not establish intact-cell permeation.
Methods and source locations
Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin
Purified membrane-model observations only; no antibacterial potency or cellular uptake claim.
Accepted manuscript p. 5 Antibiotics; p. 6 Langmuir Isotherms and Partitioning Analysis; pp. 12–13 and Figure 3C–E
Pressure–area isotherms of Re-LPS and Rd-LPS with telithromycin: Figure 3C,D compares control with 1.0, 3.0 and 10.0 μM telithromycin. Isotherms were measured at least three times per concentration and lipid type. No curve-derived decimal values extracted. — Accepted manuscript pp. 12–13, Figure 3C,D and caption; p. 6 Langmuir Isotherms
Subtype-dependent nAChR inhibition at a fixed concentration
Cell-based study · Human α7, α3β4, α4β2 and adult muscle-type α1β1δε nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. [3]
Sustained telithromycin exposure suppressed ACh-evoked currents to different extents across receptor subtypes. Muscle-receptor inhibition partially recovered after washout and was comparable to effects of azithromycin and clarithromycin.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM telithromycin
- Exposure duration
- 20-min sustained exposure; muscle-receptor recovery assessed over a further 10 min.
- Method
- Two-electrode voltage clamp, −80 mV. Figure 2 uses 10 μM ACh pulses for 10 s every 2 min; Figure 3 refers to that protocol. Currents normalized to predrug ACh responses.
- Co-treatment
- Azithromycin and clarithromycin were separate comparator exposures, not co-treatments.
- Reported limits
- Vehicle and compound supplier are not specified. Table 1 gives n = 3 to 5 without per-subtype counts; Figure 3 caption instead says at least 5 cells. Table-specific n semantics are preserved.
Methods and source locations
Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin
Heterologous cellular receptor effects; no intact-animal experiment or proven clinical adverse-event mechanism.
Electrophysiology methods; Table 1; Figures 2 and 3 and captions; Results on muscle-receptor limitation
Inhibition of ACh-evoked current at human α7 receptors after 20 min at 2 μM: Two-electrode voltage clamp at −80 mV; normalized to ACh control; Table 1 mean ± SEM, n = 3 to 5. — Table 1, telithromycin column and footnote; Figure 3 and caption
Inhibition of ACh-evoked current at human α3β4 receptors after 20 min at 2 μM: Same fixed-concentration design; Table 1 mean ± SEM, n = 3 to 5. — Table 1, telithromycin column and footnote; Figure 3 and caption
Inhibition of ACh-evoked current at human α4β2 receptors after 20 min at 2 μM: Same fixed-concentration design; Table 1 mean ± SEM, n = 3 to 5. — Table 1, telithromycin column and footnote
Inhibition of ACh-evoked current at human muscle-type receptors after 20 min at 2 μM: Table 1 mean ± SEM, n = 3 to 5; azithromycin 38 ± 10%, clarithromycin 47 ± 7% in separate exposures. Figure 2C explicitly reports n = 3. — Table 1 and footnote; Figure 2A–C and caption; Results paragraph on comparable NMJ inhibition
Concentration–inhibition profiles at neuronal nAChRs
Cell-based study · Human α3β4, α7 and α4β2 nAChRs expressed in Xenopus laevis oocytes. [3]
The reported current-inhibition potencies differed by receptor subtype; α3β4 and α7 were more sensitive to telithromycin than α4β2. These are functional receptor assay IC50 values, not antibacterial potency or treatment doses.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration series; Results identifies 10 μM as the highest concentration for the α3β4 comparison. IC50 values are endpoints, not fixed exposure concentrations.
- Method
- ACh-evoked currents normalized to control; empirical Hill concentration–inhibition fits in Figure 5, whose axis labels identify ACh 30 μM. General recording method: two-electrode voltage clamp at −80 mV.
- Co-treatment
- Azithromycin, clarithromycin and solithromycin were separate comparator profiles, not combinations.
- Reported limits
- The Figure 5 design does not separately state exposure duration or subtype-specific cell counts; duration from the fixed-concentration experiment is not imputed. No IC50 uncertainty interval is given in the Results.
Methods and source locations
Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin
Functional off-target receptor concentration–response only.
Results concentration–inhibition paragraphs; Figure 5A–F and caption
Concentration producing half-maximal inhibition of α3β4 ACh-evoked current: ACh-control-normalized currents, empirical Hill fit; Figure 5 reports responses from three to seven cells and SEM bars. Value from Results, not estimated from graph. — Results concentration-inhibition paragraph; Figure 5A,D and caption
Concentration producing half-maximal inhibition of α7 ACh-evoked current: Same concentration-response design; original approximation retained. — Results concentration-inhibition paragraph; Figure 5B,E and caption
Concentration producing half-maximal inhibition of α4β2 ACh-evoked current: Same concentration-response design; original approximation retained. — Results α4β2 paragraph; Figure 5C,F and caption